Previous 10 | Next 10 |
Q3 clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
Summary The FDA is preparing to extend its regulatory arm over LDTs. The potential for negative regulatory intervention puts OCX's strategy into serious question. OCX must navigate the new regulations and the limited resources that come with being a small-cap company while try...
There's big news for Guardant Health (NASDAQ: GH) shareholders today -- but disappointing news also. This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: ...
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30...
Guardant Health (NASDAQ: GH) did relatively well on the market Thursday. The cancer-diagnostics company's shares effectively traded sideways on a day when the S&P 500 index flopped by over 1%. Investors were cautiously optimistic about a new analyst take on the stock. St...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw Researchers can access additional modular content to...
Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announ...
Oncology diagnostics company Guardant Health (NASDAQ: GH) made its investors happy on Wednesday with an almost 4% rise in its stock price. That performance, far better than the nearly 1% slump of the S&P 500 , was due to the expansion of a collaboration deal with a top name ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
5.97%Change Percent:
Guardant Health Inc. Company Name:
GH Stock Symbol:
NASDAQ Market:
Guardant Health Inc. Website:
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...